Transcribe to Survive: Transcriptional Control of Antioxidant Defense Programs for Neuroprotection in Parkinson’s Disease
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a progressive, primarily motor disorder that is characterized by loss of dopaminergic (DA) neurons within the substantia nigra (SN). Cell death in PD has been associated with impaired mitochondrial function and increased oxidative stress. Strategies to reduce the oxidative load in DA cells may be beneficial in slowing the progression of PD. The transcription factor nuclear factor-erythroid 2 (NF-E2) related factor 2 (NRF2) is emerging as a master regulator of antioxidant defense systems, which makes it an attractive target for manipulations that aim to increase cellular resistance to oxidative stress. Peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator-1 alpha (PGC1alpha) is a regulator of mitochondrial biogenesis genes that simultaneously upregulates many genes known to protect against oxidative stress. Pgc-1alpha knockout mice show enhanced susceptibility to SN neuronal loss following MPTP exposure, whilst overexpression of Pgc-1alpha appears to protect against oxidative stress in vitro. This makes PGC-1alpha a highly attractive target for neuroprotective therapies in PD. This review will explore the mechanisms behind the induction of NRF2 and PGC-1alpha in response to oxidative stress and identify common pathways that may provide targets for upregulating antioxidant defense programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 1×
“…a double-glycine repeat domain (DGR or Kelch domain; amino acids 315–598) which binds to both F-actin and NRF2 to sequester NRF2 in the cytoplasm (73, 86, 198), and a C-terminal region (CTR; amino acids 599–624) which is also thought to participate in the binding of KEAP1 to NRF2 (41, 192).”
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Some studies suggest that somatic mtDNA point mutations and deletions accumulate with age and may contribute to mitochondrial dysfunction in aging and in PD (9, 22, 55, 103, 186, 194, 200).”
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
Self-citationKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224 · cited 2×
“KEAP1 acts as both an oxidant sensor and as a substrate adaptor protein for NRF2 degradation by Cul3-BTB KEAP1 E3 ligase (29, 47, 96, 221).”
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 1×
“After Lin et al., 2005 (114a) and Knutti and Kralli, 2001 (95).”
Puigserver, P., & Spiegelman, B. M. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0012 · Cited by 2,076
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947 · cited 1×
“Under conditions of oxidative stress, reactive cysteine residues within the IVR of KEAP1 may be differentially modified (40 protein that blocks ubiquitination of NRF2 but does not release the Neh2 domain of NRF2 from KEAP1 (97, 193).”
Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffer, P. J., Huang, T.-T., Bos, J. L., Medema, R. H., & Burgering, B. M. T. (2002) · Nature · doi:10.1038/nature01036 · Cited by 1,580
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 2×
“Some studies suggest that somatic mtDNA point mutations and deletions accumulate with age and may contribute to mitochondrial dysfunction in aging and in PD (9, 22, 55, 103, 186, 194, 200).”
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
Rushmore, T. H., Morton, M. R., & Pickett, C. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99004-6 · Cited by 1,464
Bohmann, D., Bos, T. J., Admon, A., Nishimura, T., Vogt, P. K., & Tjian, R. (1987) · Science · doi:10.1126/science.2825349 · Cited by 1,321 · cited 1×
“…CREB/activating transcription factor (ATF) family of bZIP transcription factors bind (127), the 12-O-tetradecanoylphorbol-13-acetate (TPA) response-element (TRE; TGACTCA) to which the transcription factor activating protein-1 (AP-1) binds (15) and the antioxidant response element (ARE; TGACNNNGC).”
Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null Mice
Lin, J., Wu, P.-H., Tarr, P. T., Lindenberg, K. S., St-Pierre, J., Zhang, C.-Y., Mootha, V. K., Jäger, S., Vianna, C. R., Reznick, R. M., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.013 · Cited by 1,162
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Klivenyi, P., Andreassen, O. A., Ferrante, R. J., Dedeoglu, A., Mueller, G., Lancelot, E., Bogdanov, M., Andersen, J. K., Jiang, D., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00001.2000 · Cited by 1,111
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 1×
“As previously discussed, there may be an increased risk of cancer associated with the constitutive systemic over-expression of antioxidant defense master regulators such as NRF2 (138, 175, 207).”
Cullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845 · cited 15×
“, 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4,1,2,3,6-tetrahydropyridine; mtDNA, mitochondrial DNA; NAC, N-acetyl cysteine; Neh, Nef2 ECH homology; NF-E2, nuclear factor-erythroid 2; NF-(cid:5) B, nuclear factor kappa beta; NQO1, NAD(P)H quinone oxidoreductase 1; NRF1, nuclear factor erythroid 2-related factor 1; NR…”
InfluentialRedox Regulation of Forkhead Proteins Through a p66shc -Dependent Signaling Pathway
Nemoto, S., & Finkel, T. (2002) · Science · doi:10.1126/science.1069004 · Cited by 818
Expression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759 · cited 2×
“…a double-glycine repeat domain (DGR or Kelch domain; amino acids 315–598) which binds to both F-actin and NRF2 to sequester NRF2 in the cytoplasm (73, 86, 198), and a C-terminal region (CTR; amino acids 599–624) which is also thought to participate in the binding of KEAP1 to NRF2 (41, 192).”
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757 · cited 15×
“, 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4,1,2,3,6-tetrahydropyridine; mtDNA, mitochondrial DNA; NAC, N-acetyl cysteine; Neh, Nef2 ECH homology; NF-E2, nuclear factor-erythroid 2; NF-(cid:5) B, nuclear factor kappa beta; NQO1, NAD(P)H quinone oxidoreductase 1; NRF1, nuclear factor erythroid 2-related factor 1; NR…”
InfluentialThomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 1×
“As previously discussed, there may be an increased risk of cancer associated with the constitutive systemic over-expression of antioxidant defense master regulators such as NRF2 (138, 175, 207).”
Cytokine Stimulation of Energy Expenditure through p38 MAP Kinase Activation of PPARγ Coactivator-1
Puigserver, P., Rhee, J., Lin, J., Wu, Z., Yoon, J. C., Zhang, C.-Y., Krauss, S., Mootha, V. K., Lowell, B. B., & Spiegelman, B. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00390-2 · Cited by 732
Handschin, C., Rhee, J., Lin, J., Tarr, P. T., & Spiegelman, B. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1232352100 · Cited by 729
PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells
VALLE, I., ALVAREZBARRIENTOS, A., ARZA, E., LAMAS, S., & MONSALVE, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.01.026 · Cited by 556
Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway
Cullinan, S. B., & Diehl, J. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.018 · Cited by 554
Protein Nitration in Parkinsonʼs Disease
Good, P. F., Hsu, A., Werner, P., Perl, D. P., & Olanow, C. W. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199804000-00006 · Cited by 540
Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3β Inactivation
Thornton, T. M., Pedraza-Alva, G., Deng, B., Wood, C. D., Aronshtam, A., Clements, J. L., Sabio, G., Davis, R. J., Matthews, D. E., Doble, B., et al. (2008) · Science · doi:10.1126/science.1156037 · Cited by 484
Lerin, C., Rodgers, J. T., Kalume, D. E., Kim, S.-H., Pandey, A., & Puigserver, P. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.013 · Cited by 443
Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Czubryt, M. P., McAnally, J., Fishman, G. I., & Olson, E. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337639100 · Cited by 418
Mitochondrial point mutations do not limit the natural lifespan of mice
Vermulst, M., Bielas, J. H., Kujoth, G. C., Ladiges, W. C., Rabinovitch, P. S., Prolla, T. A., & Loeb, L. A. (2007) · Nature Genetics · doi:10.1038/ng1988 · Cited by 404
Pitkanen, S., & Robinson, B. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118798 · Cited by 388 · cited 1×
“CI inhibition by MPTP (100, 201) or rotenone (11, 172), which increases free radical production in vitro and in vivo (61, 105, 144, 146, 171, 176, 220), induces the accumulation of insoluble (cid”
The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm
Zipper, L. M., & Mulcahy, R. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206530200 · Cited by 366 · cited 1×
“…Tram-track, Bric-a-brac domain (BTB; amino acids 61–179) which is highly conserved and indispensable for homodimerization, and KEAP1 function (225), an intervening region (IVR; amino acids 180–314) which is relatively rich in cysteine residues, a double-glycine repeat domain (DGR or Kelch…”
BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE
MANN, V. M., COOPER, J. M., KRIGE, D., DANIEL, S. E., SCHAPIRA, A. H. V., & MARSDEN, C. D. (1992) · Brain · doi:10.1093/brain/115.2.333 · Cited by 346 · cited 1×
“Impaired mitochondrial CI (CI) activity was identified in platelets (56, 104, 139) and the SN (119, 167) of PD patients, and reduced levels of CI subunits have also been demonstrated (125).”
Fan, M., Rhee, J., St-Pierre, J., Handschin, C., Puigserver, P., Lin, J., Jäeger, S., Erdjument-Bromage, H., Tempst, P., & Spiegelman, B. M. (2004) · Genes & Development · doi:10.1101/gad.1152204 · Cited by 309
Anderson, R. M., Barger, J. L., Edwards, M. G., Braun, K. H., O’Connor, C. E., Prolla, T. A., & Weindruch, R. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2007.00357.x · Cited by 283
Calkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247
Chinta, S. J., Kumar, M. J., Hsu, M., Rajagopalan, S., Kaur, D., Rane, A., Nicholls, D. G., Choi, J., & Andersen, J. K. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3885-07.2007 · Cited by 145 · cited 1×
“Induction of GSH deficiency in cell lines (79) and in mice (26) leads secondarily to a specific defect in CI activity.”
Kim, T. K., Kim, T. H., & Maniatis, T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12191 · Cited by 109
Cited by
The complexity of the Nrf2 pathway: beyond the antioxidant response
Huang, Y., Li, W., Su, Z.-Y., & Kong, A.-N. T. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.001 · Cited by 445
Mitochondrial Regulation of Cell Cycle and Proliferation
Antico Arciuch, V. G., Elguero, M. E., Poderoso, J. J., & Carreras, M. C. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4085 · Cited by 434
Ryan, S. D., Dolatabadi, N., Chan, S. F., Zhang, X., Akhtar, M. W., Parker, J., Soldner, F., Sunico, C. R., Nagar, S., Talantova, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.009 · Cited by 434
Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease
Rojo, A. I., Innamorato, N. G., Martín‐Moreno, A. M., De Ceballos, M. L., Yamamoto, M., & Cuadrado, A. (2010) · Glia · doi:10.1002/glia.20947 · Cited by 375
NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage
Xiong, W., MacColl Garfinkel, A. E., Li, Y., Benowitz, L. I., & Cepko, C. L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79735 · Cited by 280
Metadata
- Authors
- Clark, J., & Simon, D. K.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2009-03
- Volume
- 11
- Issue
- 3
- Pages
- 509-528
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2081854210
- Cited by
- 93
- References
- 44
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.